Associated Papers
Pharmacogenetics and Molecular Ancestry of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Ecuadorian Subjects with Type 2 Diabetes Mellitus.
Ortega-Ayala A et al.
Pharmaceuticals (basel, Switzerland), 2025
41011206 (PubMed )
Supplement: pharmaceuticals-18-01335-s001.zip › pharmaceuticals-3834233-supplementary › Table_S7.pdf
Molecular Ancestry Across Allelic Variants of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Mexican-Mestizo DMT2 Patients.
Ortega-Ayala A et al.
Biomedicines, 2025
40426982 (PubMed )
Supplement: biomedicines-13-01156-s001.zip › Table_S1.pdf
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG et al.
Cancer Drug Resistance (alhambra, Calif.), 2024
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.
Yee SW et al.
Biorxiv : the Preprint Server for Biology, 2023
37333090 (PubMed )
Supplement: media-2.xlsx › S2_gnomAD_v2.1
Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients.
Estrada N et al.
Journal of Clinical Medicine, 2022
Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.
Alves R et al.
International Journal of Molecular Sciences, 2022
36077209 (PubMed )
Supplement: ijms-23-09815-s001.zip › ijms-1852648-supplementary.pdf
Select a paper to view details